Clinical Trial Update: Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and immunogenicity of a newly developed 23-valent pneumococcal polysaccharide vaccine in Chinese adults and children has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Pneumococcal polysaccharide vaccine (23-valent) (pneumococcal polysaccharide vaccine (23-valent))

Snippet

Sponsor: Walvax Biotechnology Co., Ltd. | Conditions: Pneumococcal Infectious Diseases | Phase 3 | Status: COMPLETED